These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23959464)

  • 1. Reversibility of regorafenib effects in hepatocellular carcinoma cells.
    D'Alessandro R; Refolo MG; Lippolis C; Messa C; Cavallini A; Rossi R; Resta L; Di Carlo A; Carr BI
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):869-77. PubMed ID: 23959464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1237-1245. PubMed ID: 25907508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
    D'Alessandro R; Refolo MG; Lippolis C; Giannuzzi G; Carella N; Messa C; Cavallini A; Carr BI
    BMC Cancer; 2014 May; 14():351. PubMed ID: 24885890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.
    Carr BI; D'Alessandro R; Refolo MG; Iacovazzi PA; Lippolis C; Messa C; Cavallini A; Correale M; Di Carlo A
    J Cell Physiol; 2013 Jun; 228(6):1344-50. PubMed ID: 23169148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery.
    Carr BI; Cavallini A; Lippolis C; D'Alessandro R; Messa C; Refolo MG; Tafaro A
    J Cell Physiol; 2013 Feb; 228(2):292-7. PubMed ID: 22777740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells.
    Tsai JJ; Pan PJ; Hsu FT
    Oncol Rep; 2017 Feb; 37(2):1036-1044. PubMed ID: 28000898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
    He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
    Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1.
    Lippolis C; Refolo MG; D'Alessandro R; Carella N; Messa C; Cavallini A; Carr BI
    J Exp Clin Cancer Res; 2015 Sep; 34(1):90. PubMed ID: 26329608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice.
    Weng MC; Wang MH; Tsai JJ; Kuo YC; Liu YC; Hsu FT; Wang HE
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29535278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.
    Ou DL; Chen CW; Hsu CL; Chung CH; Feng ZR; Lee BS; Cheng AL; Yang MH; Hsu C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib as treatment for patients with advanced hepatocellular cancer.
    Thillai K; Srikandarajah K; Ross P
    Future Oncol; 2017 Oct; 13(25):2223-2232. PubMed ID: 28766967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COL5A2 drives regorafenib resistance-induced metastatic phenotype via reducing LIFR expression in hepatocellular carcinoma.
    Zhang S; Xue X; Chen F; Yang Y; Zhang N; Chen Y; Wu W; Wang J; Zheng N
    Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(7):997-1010. PubMed ID: 38818582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.
    Yu CC; Huang SY; Chang SF; Liao KF; Chiu SC
    Molecules; 2020 May; 25(10):. PubMed ID: 32466169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shufeng Jiedu Capsule and its active ingredients induce apoptosis, inhibit migration and invasion, and enhances doxorubicin therapeutic efficacy in hepatocellular carcinoma.
    Xia J; Rong L; Sawakami T; Inagaki Y; Song P; Hasegawa K; Sakamoto Y; Tang W
    Biomed Pharmacother; 2018 Mar; 99():921-930. PubMed ID: 29710492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration.
    Xiao Y; Yan W; Guo L; Meng C; Li B; Neves H; Chen PC; Li L; Huang Y; Kwok HF; Lin Y
    Mol Med Rep; 2017 Feb; 15(2):941-947. PubMed ID: 28035421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
    Wu LW; Zhou DM; Zhang ZY; Zhang JK; Zhu HJ; Lin NM; Zhang C
    Biochem Biophys Res Commun; 2019 May; 512(4):852-858. PubMed ID: 30929918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
    Wei G; Wang M; Hyslop T; Wang Z; Carr BI
    Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib: a newly approved drug for advanced hepatocellular carcinoma.
    Kyrochristos ID; Ziogas DE; Roukos DH
    Future Oncol; 2017 Aug; 13(19):1665-1668. PubMed ID: 28613123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.